This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
B cell lymphoma	Tumor necrosis factor receptor superfamily member 9 (TNFRSF9; 4-1BB; CD137)	Studies in mice suggest that CD137 functions as a tumor suppressor and could be useful as a marker for B cell lymphoma. In mice, CD137 deficiency significantly increased the risk of developing lymphoma compared with that of wild-type controls ($p < 0.0001$). Next steps could include developing compounds that increase CD137 expression and evaluating them in animal models of lymphoma. BMS-663513, an agonistic mAb against CD137 from Bristol-Myers Squibb Co., is in Phase I/II testing to treat cancer.	Patent and licensing status unavailable	Middendorp, S. <i>et al. Blood</i> ; published online July 16, 2009; doi:10.1182/blood-2009-03-208215 Contact: Jannie Borst, The Netherlands Cancer Institute, Amsterdam, the Netherlands e-mail: j.borst@nki.nl
<i>SciBX</i> 2(31); doi:10.1038/scibx.2009.1216 Published online Aug. 13, 2009				